Latest Breaking News On - Lugui qiu - Page 1 : vimarsana.com

Innovent and IASO Bio Present Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO® (Equecabtagene Autoleucel) at IMS 2023

/PRNewswire/ Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes.

Hong kongUnited statesLugui qiuEli lillyInnovent biologicsChunrui liEquecabtagene autoleucelAdimab incyteIncyte corporationPrnewswire innovent biologics incHuazhong university of science technologyTongji medical collegeInternational myeloma societyChina national medical products administrationMd anderson cancer centerChinese academy of medical science hematology hospital

Innovent and IASO Bio Present Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO® (Equecabtagene Autoleucel) at IMS 2023

Innovent and IASO Bio Present Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO® (Equecabtagene Autoleucel) at IMS 2023
sina.com.hk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com.hk Daily Mail and Mail on Sunday newspapers.

United statesHong kongEli lillyAdimab incyteChunrui liLugui qiuEquecabtagene autoleucelIncyte corporationInnovent biologics incMd anderson cancer centerInternational myeloma societyTongji medical collegeChina national medical products administrationHuazhong university of science technologyChinese academy of medical science hematology hospitalComplete response

IASO Bio Presents Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO® (Equecabtagene Autoleucel) at IMS 2023

/PRNewswire/ IASO Bio, a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody.

Lugui qiuAdimab incyteChunrui liEli lillyA equecabtagene autoleucelEquecabtagene autoleucelInnovent biologicsInnovent biologics incInternational myeloma societyHuazhong university of science technologyChinese academy of medical science hematology hospitalMd anderson cancer centerTongji medical collegeChina national medical products administrationComplete responseAbstract code

Equecabtagene Autoleucel Approved in China for Relapsed/Refractory Multiple Myeloma

China’s National Medical Products Administration has approved the new drug application for equecabtagene autoleucel for the treatment of adult patients with relapsed or refractory multiple myeloma who previously received 3 or more lines of therapy, including a proteasome inhibitor and an immunomodulatory drug.

Chunrui liLugui qiuTongji medical collegeChinese academy of medical science hematology hospitalChina national medical products administrationHuazhong university of science technologyNational medical products administrationChinese academyMedical science hematology hospitalTongji hospitalHuazhong universityEquecabtagene autoleucelCart cell therapyMultiple myelomaNational medical products administrationFumanba 1

IASO Bio and Innovent Announce the NMPA Approval of the New Drug Application for Equecabtagene Autoleucel, the World s First Fully-human BCMA CAR-T Therapy, for the Treatment of Relapsed and/or Refrac

IASO Bio and Innovent Announce the NMPA Approval of the New Drug Application for Equecabtagene Autoleucel, the World s First Fully-human BCMA CAR-T Therapy, for the Treatment of Relapsed and/or Refrac
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesHong kongRhui zhouEquecabtagene autoleucelLugui qiuEli lillyAdimab incyteChunrui liJinghua zhangInnovent biologicsInnovent biologics incTongji medical collegeChinese academy of medical science hematology hospitalChina national medical products administrationMd anderson cancer centerHuazhong university of science technology